

You are cordially invited to attend a professional lecture featuring

UBRELVY®: Acute Treatment Option for Migraine

PRESENTED VIA WEBCAST BY:

Stefanie Brackin, NP

NEA Baptist Neurology Jonesboro, AR

Tuesday, July 20, 2021 at 6:30 PM

Login: http://medforce.adobeconnect.com/mid120049/

DIAL-IN INFORMATION:

Phone number: (800) 326-0013 Passcode: 5915258

Please RSVP for this program using the following link:

https://www.ubrelvylive.com/register/120049

For questions, contact your AbbVie Representative Kristen Mangrum Phone: 0 Email: kristen.mangrum@abbvie.com

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin). **Adverse Reactions:** The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Please also see accompanying full Prescribing Information.

This promotional event is brought to you by AbbVie and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.

